G2083, Office or other outpatient visit for the evaluation and management of an
HCPCS/CPT
Prior Authorization
No Prior Auth Required
Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
0.70
Facility
$31.06
Non-Facility
$1356.08
Documentation Required
- Enroll all treated individuals in the REMS registry to characterize risks and support safe use.
- Evaluate therapeutic benefit at the end of the induction phase to decide on continuation of treatment.
- Pharmacies and healthcare settings that dispense esketamine must be certified.
- Ensure each individual is informed about risks of sedation/dissociation and the need for monitoring.
Key Coverage Criteria
- Treatment-resistant depression: induction weeks 1-4 — twice weekly dosing (day 1 start 56 mg; subsequent doses 56 mg or 84 mg); maintenance weeks 5-8 — once weekly (56 mg or 84 mg); from week 9 onward — every 2 weeks or once weekly (56 mg or 84 mg); individualize to the least frequent dosing to maintain remission/response.
- Major depressive disorder with acute suicidal ideation or behavior: 84 mg twice weekly for 4 weeks (may reduce to 56 mg twice weekly for tolerability); use beyond 4 weeks has not been systematically evaluated.
- Treatment-resistant depression: induction weeks 1-4 — twice weekly dosing (day 1 start 56 mg; subsequent doses 56 mg or 84 mg); maintenance weeks 5-8 — once weekly (56 mg or 84 mg); from week 9 onward — every 2 weeks or once weekly (56 mg or 84 mg); individualize to the least frequent dosing to maintain remission/response.
- Major depressive disorder with acute suicidal ideation or behavior: 84 mg twice weekly for 4 weeks (may reduce to 56 mg twice weekly for tolerability); use beyond 4 weeks has not been systematically evaluated.
- Treatment-resistant depression: induction weeks 1-4 — twice weekly dosing (day 1 start 56 mg; subsequent doses 56 mg or 84 mg); maintenance weeks 5-8 — once weekly (56 mg or 84 mg); from week 9 onward — every 2 weeks or once weekly (56 mg or 84 mg); individualize to the least frequent dosing to maintain remission/response.
- Major depressive disorder with acute suicidal ideation or behavior: 84 mg twice weekly for 4 weeks (may reduce to 56 mg twice weekly for tolerability); use beyond 4 weeks has not been systematically evaluated.
4 Active Policies
BCBSIL-RX501.105, Esketamine Nasal Spray
BCBSMT-RX501.105, Esketamine Nasal Spray
BCBSNM-RX501.105, Esketamine Nasal Spray
BCBSOK-RX501.105, Esketamine Nasal Spray
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.